DEF: Jasper Therapeutics Sets 2026 Annual Meeting Date

Jasper Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for July 31, 2026, to elect directors, ratify auditor appointment, and vote on executive compensation.

Summary

• Jasper Therapeutics, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on Friday, July 31, 2026, at 10:00 a.m. Pacific Time.
• The meeting's agenda includes the election of two Class II directors, ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026, and an advisory vote on executive compensation.
• The record date for determining stockholders entitled to vote is June 5, 2026.
• Proxy materials will be made available online on or about June 18, 2026.
• The company encourages stockholders to vote by proxy in advance of the meeting.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it outlines standard corporate governance procedures and upcoming shareholder votes, with no immediate negative financial news but also no significant positive operational updates.

Positives

• The company is holding its annual meeting to ensure shareholder engagement and governance.
• The virtual meeting format is intended to provide expanded access to stockholders, lower costs, and align with sustainability goals.
• Stockholders have the opportunity to vote on director elections, auditor ratification, and executive compensation.
• The board recommends voting FOR the proposed director nominees, auditor ratification, and executive compensation.

Risks

• The classification of the Board of Directors into three staggered classes may delay or prevent a change in control of the Company.
• The company's financial statements for the year ended December 31, 2025, reported a net loss of $75.8 million.

Future Outlook

The filing does not contain specific forward-looking financial guidance but outlines proposals for the upcoming annual meeting, including director elections and auditor ratification for the fiscal year ending December 31, 2026.

Management Comments

• "We cordially invite you to attend the 2026 Annual Meeting of Stockholders..."
• "In order to provide expanded access to our stockholders, our board of directors has determined to hold a live audio webcast in lieu of an in-person meeting."
• "The virtual-only approach also lowers costs and aligns with our broader sustainability goals."
• "We encourage you to vote your shares prior to the Annual Meeting either by Internet or by proxy card to help make this meeting format as efficient as possible."
• "YOUR VOTE IS IMPORTANT. Whether or not you plan to attend the Annual Meeting, we urge you to submit your vote via the Internet or mail as soon as possible to ensure that your shares are represented."
• "Our Board recommends a vote: FOR the election of Judith Shizuru, M.D., Ph.D. and Tom Wiggans as Class II directors; FOR the ratification of the appointment of PricewaterhouseCoopers LLP...; and FOR the approval of the compensation of our named executive officers..."
• "We believe our executive compensation program fulfills these goals and is reasonable, competitive and aligned with our performance and the performance of our executives."

Industry Context

StockSavvy.ai notes that this proxy statement is typical for a publicly traded biotechnology company preparing for its annual shareholder meeting, focusing on standard governance procedures like director elections, auditor ratification, and executive compensation approval.

Corporate Governance

Related Party Transactions

• Dr. Judith Shizuru, a Board member and significant stockholder, previously had a consulting agreement for which she waived payments since January 1, 2025.
• Employment agreements with executive officers are detailed in the Executive Compensation section.
• Stock and option awards have been granted to directors and named executive officers.

Stakeholder Impact

• Shareholders: Opportunity to vote on key corporate matters, including director elections and executive compensation, and to receive information on company performance and governance.
• Management and Employees: Subject to executive compensation plans, stock options, and insider trading policies; former executives Ronald Martell and Edwin Tucker have had their employment terminated.
• Auditors: PricewaterhouseCoopers LLP is proposed for reappointment, with fees for fiscal years 2025 and 2024 disclosed.

Next Steps

• Stockholders to vote on the election of directors, ratification of the independent auditor, and advisory approval of executive compensation.
• The company will file a Current Report on Form 8-K with preliminary voting results within four business days after the Annual Meeting.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new operational or financial performance data that would warrant a change in investment strategy. It confirms upcoming governance votes and standard procedures. Investors should rely on other filings for performance-based decisions.

Keywords

Proxy Statement, Annual Meeting, Director Election, Auditor Ratification, Executive Compensation, Jasper Therapeutics, Stockholder Vote, Corporate Governance